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Introduction: Retinal vein occlusion (RVO) is one of the most common retinal vascular disorders affecting
ocular vessels. Few studies, with conflicting results and conducted in limited study populations, have
hypothesised the role of high levels of lipoprotein (a) [Lp(a)] in the occurrence of RVO. The aim of this
study was to investigate, in a large group of RVO patients, the role of such an emerging thrombophilic
parameter on the pathogenesis of RVO.
Materials and methods: We compared 262 patients [median age: 66 years (15–88); 122 M, 140 F] with
262 age- and sex-comparable healthy subjects.
Results: Circulating concentrations of Lp(a) were found to be significantly different in patients when
compared to healthy subjects [189 (60–1898)mg/L vs. 119.5 (6–1216)mg/L; p<0.0001, respectively].
No significant differences were observed relating to the different types of occlusion (central or branch
occlusion). In order to investigate the possible association between high Lp(a) levels and the disease we
performed a logistic regression analysis. In the univariate analysis, Lp(a) levels > 300mg/L were found
to be associated with an increased risk of RVO (OR: 2.39, 95%CI 1.39–3.59; p<0.0001). Following this,
three models of multivariate analysis were performed, firstly by adjusting for age, gender, and tradi-
tional cardiovascular risk factors, secondly for triglycerides and thirdly for homocysteine levels. In all
the models, Lp(a) levels > 300mg/L confirmed their role as a risk factor for RVO [first model, OR: 2.15
(95%CI 1.39–3.32), p=0.0001; second model, OR: 3.11 (95%CI 1.77–5.62), p<0.00001; third model, OR:
3.48 (95%CI 1.88–6.43), p<0.00001].
Conclusions: This study reports that, in a large population of RVO patients, high Lp(a) concentrations are
significantly related to RVO, independent from other traditional and emerging risk factors, suggesting
that they may play a role in its pathogenesis.
© 2009 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Retinal vein occlusion (RVO) is a potentially vision-threatening
retinal vascular disorder, representing the second most frequent
disease of the eye [1,2]. RVO is a relatively frequent disease which
has been reported to be associated with an increased risk of mor-
tality from cardiovascular diseases [3]. To date, the pathogenesis
of RVO is not fully understood. Atherosclerosis is considered to
be the most important underlying condition and several tradi-
tional risk factors (hypertension, diabetes, and smoking habit)
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have been identified to play a role in the pathogenesis of the
disease [4].
We have recently reported a role for emerging thrombophilic
risk factors, haemorheology, and B-group vitamins on the occur-
rence of RVO [5–8], but an ongoing issue is the role of dyslipidemia
and lipid parameters in the pathogenesis of RVO. Lipoprotein (a)
[Lp(a)] is a specific class of lipoprotein particle composed of a sin-
gle copyof apolipoproteinB-100 linked to an apo(a) component [9].
Due to its similarity with low-density lipoprotein particles, Lp(a)
has been thought to have proatherogenic properties. Moreover,
Lp(a) has been also demonstrated to have prothrombotic prop-
erties, mainly due to the high homology between certain kringle
domains of apo(a) of Lp(a) and that of the fibrinolytic proenzyme
plasminogen. In recent years, there has been increasing interest
in the possible association between alterations of Lp(a) and RVO,
but no conclusive data have been obtained [5,10–16]. Some studies
0021-9150/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
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reported increased levels of Lp(a) in RVO patients when compared
to healthy controls [10–15], whereas others did not support these
findings [5,16]. The aim of this retrospective case–control study
was therefore to evaluate, in a large population of RVO patients,
the possible association between Lp(a) and the occurrence of RVO.
2. Materials and methods
2.1. Study population
The study population comprised 262 consecutive patients [122
males, 140 females with a median age of 66 years (range: 15–88)]
with an RVO diagnosis who had been referred to the Thrombosis
Centre of the University of Florence, Italy. RVO was diagnosed in all
patients within a period of 1–3 months before the examination, at
the Department of Oto-Neuro-Ophthalmogical Surgical Sciences of
theUniversity of Florence, Italy. RVOwas diagnosed by ophthalmo-
scopic fundus examination revealing disc swelling, venous dilation
or tortuosity, retinal haemorrhages, and cotton-wool spots and by
fluorescein angiographydemonstrating extensive areas of capillary
closure, venous filling defects and increased venous transit time.
The control population comprised262healthy subjects, selected
to be of comparable age and gender to the patients [123 males, 139
females; median age: 65.5 years (range: 21–84)] from the staff of
the University of Florence and/or from their friends or partners.
Patients and control subjects with a personal history of glau-
coma or cardiovascular disease were excluded from the study. In
order to identify symptom-free subjects and patients excluding
those who were suspected of having any form of vascular disease,
a detailed interview addressing personal and familial history was
performed.
The subjectswere classifiedashavinghypertension according to
the guidelines of The European Society of Hypertension/European
Society of Cardiology [17] or if they reported taking antihyperten-
sive medication, as verified by the interviewer. Diabetic subjects
were defined in line with the American Diabetes Association [18]
or on the basis of self-reported data (if confirmed by medication
or chart review). Dyslipidemia was defined following the criteria
of the ATP III Expert Panel of the US National Cholesterol Educa-
tion Program [19]. Current smoking status was determined at the
timeof physical examination. All participants gave signed informed
consent; the studywas approved by the local Ethics Committee and
complies with the Declaration of Helsinki.
2.2. Blood measurements
Blood samples were collected from the antecubital vein into
evacuated plastic tubes (Vacutainer), after an overnight fast. Sera
samples were obtained by centrifuging blood collected in evac-
uated tubes without anticoagulant at 2000× g for 10min at
4 ◦C, subsequently stored at −20 ◦C. Lp(a) levels were measured
using the commercially availabledirect-bindingdoubleMAb-based
method (Mercodia Apo (a) ELISA, Pharmacia Diagnostics, Uppsala,
Sweden). Mercodia Apo (a) ELISA is a solid phase two-site enzyme
immunoassay. It is basedon thedirect sandwich technique inwhich
twomonoclonal antibodies aredirected towards separate antigenic
determinants on the apolipoprotein (a) molecule. It is calibrated
using a highly purified, fully validated commercial Lp(a) prepara-
tion. TheMercodia assay’s isoform independent detection of apo(a)
is reported in the study by Dembisnki et al. [20]. The results are
expressed in mg/dL, where 1U of apo(a) is approximately equal to
0.7mg of Lp(a) (Mercodia Manual) [21–23].
The lipid profile was assessed by conventional methods. To
determine homocysteine, whole venous blood was collected in
tubes containing ethylenediaminotetracetate (EDTA) 0.17mol/L,
immediately put in ice and centrifuged within 30min at 4 ◦C
(1500× g for 15min). The plasma levels of total homocysteine (free
and protein bound) were determined by fluorescence polarization
immunoassay (IMX Abbott Laboratories, Oslo, Norway). PAI-1 lev-
els were determined by immunoenzymatic assay (Asserachrome
PAI-1, Diagnostica Stago, Asnieres, France).
2.3. Statistical analysis
Statistical analysis was performed using the SPSS (Statistical
Package for Social Sciences, Chicago, USA) software for Win-
dows (Version 13.0). The non-parametric Mann–Whitney test for
unpaired data was used for comparisons between single groups.
The Chi2-test was used to test for proportions. A general linear
model, after adjustment for age, gender, smoking habit, hyperten-
sion, anddiabeteswas conducted in order to investigate differences
in Lp(a) between the patients and controls.
A logistic regression analysis was used to evaluate the risk of
RVO according to Lp(a) levels > 300mg/L. Variables which showed,
at univariate analysis, a significant association with the disease
were introduced into the multivariate model. During multivariate
analysis, a first model (Model 1) was created by adjusting for age,
gender, smoking habit, diabetes and hypertension. Subsequently, a
second model (Model 2) was created by also adjusting for triglyc-
erides’ levels. Finally, a further fully adjusted model was created by
introducing some thrombophilic risk factors such as homocysteine
and PAI-1 levels, which have been demonstrated to be associated
with RVO [5–7]. Odds ratios (OR) and 95% confidence intervals (CI)
arepresented.Ap-value <0.05wasconsidered to indicate statistical
significance.
3. Results
Demographic, clinical and laboratory characteristics of the study
population are reported in Table 1. Among the traditional cardio-
vascular risk factors, hypertension, smoking habit and diabetes, but
not dyslipidemia, were significantlymore frequent in patients than
in healthy subjects.
Lp(a) levels were found to be significantly (p<0.0001) differ-
ent between patients and controls, with a median value of 189
(range: 6–1898)mg/L in patients compared to 119.5 (6–1216)mg/L
in healthy controls. This significance was also confirmed using a
general linear model adjusted for age, gender, smoking habit, dia-
betes, andhypertension. Furthermore, Lp(a) levels above thecut-off
for an increased risk of thrombotic vascular diseases (>300mg/L)
were observed in a significantly (p<0.0001) higher proportion of
patients (n=90, 34.4%) than healthy controls (n=47, 17.9%).
Table 1
Clinical and laboratory characteristics of the study population.
Variable Patients
(n=262)
Healthy subjects
(n=262)
p-value
Age (years)a 66 (15–88) 65 (21–84) 0.6
Males/Females, n 122/140 123/139 0.9
Hypertension, n (%) 124 (47.3) 38 (14.5) <0.0001
Smoking habit, n (%) 69 (26.3) 43 (16.4) 0.006
Dyslipidemia, n (%) 86 (32.8) 68 (26) 0.08
Diabetes, n (%) 35 (13.4) 18 (6.9) 0.01
Lipoprotein (a)a 189 (6–1898) 119.5 (6–1216) <0.0001
Total cholesterol, mg/dLb 221.5±44.2 213.8±45.1 0.1
LDL-cholesterol, mg/dLb 122.6±37.5 110.2±40.7 0.7
HDL-cholesterol, mg/dLb 57.2±16.3 60.9±15.3 0.3
Triglycerides, mg/dLb 145.5±37.5 113.9±59.9 <0.0001
PAI-1, UI/Lb 29.9±10.6 18.6±12.3 <0.001
Homocysteine, mol/La 12.4 (5.9–53.4) 9.3 (4.4–66) <0.0001
a Median and (range).
b Mean± SD.
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Fig. 1. Logistic regression analyses on the possible association between high Lp(a)
levels and RVO. Model 1: Adjusted for age, gender, hypertension, diabetes, smoking
habit. Model 2: Adjusted for age, gender, hypertension, diabetes, smoking habit,
and triglycerides’ levels. Model 3: Adjusted for age, gender, hypertension, diabetes,
smoking habit, triglycerides, homocysteine and PAI-1 levels.
Subsequently, we investigatedwhether Lp(a) levelswere differ-
ent according to the typeof thedisease, as reportedbyeither central
or peripheral localization of the retinal thrombosis. Both types of
the disease showed significantly higher Lp(a) levels compared to
the control group (p<0.0001 for all), but no significant differences
between the different types of the disease were observed [central
retinal vein occlusion: 186 (9–1828)mg/L vs. branch retinal vein
occlusion: 190 (6–1285)mg/L; p=0.3].
Finally, inorder to search for apossible associationbetweenhigh
levels of Lp(a) and RVO we performed a logistic regression analysis,
which showed, at the univariate analysis, a significant association
between Lp(a) >300mg/L (Fig. 1) and the disease. After adjustment
for age, sex, hypertension, smoking habit, diabetes (Fig. 1, Model
1), triglycerides’ levels (Fig. 1, Model 2) as well as for homocysteine
and PAI-1 levels (Fig. 1, Model 3), high levels of Lp(a) remained
significantly associated with the disease.
4. Discussion
The present case–control study performed in a consecutive
number of RVO patients reported a significant association between
alterations of Lp(a) and the occurrence of retinal vein occlusive
disease. Indeed, patients with Lp(a) levels above the established
cut-off for an increased riskof vascular thrombosiswere found tobe
associated with an increased risk of RVO, after multiple corrections
for confounding factors.
To the best of our knowledge, this is the largest study which has
assessed the possible association between Lp(a) and RVO. Lp(a) is
an emerging cardiovascular risk factor consisting of a low-density
lipoprotein core associated with the apolipoprotein (a) [9]. Due
to its structural homologies with plasminogen and cholesterol
molecules, Lp(a) has been found tobe implicated in the inhibitionof
fibrinolysis as well as in atherogenesis. Currently, epidemiological
evidence has reported a pathogenetic role for high levels of Lp(a)
in the occurrence of both arterial and venous thrombotic diseases
[24,25] whereas few and conflicting results have been obtained
relating to the occurrence of RVO [10–16].
In the present study we found significantly elevated concentra-
tions of Lp(a) in patients with RVO, with no differences between
central and peripheral localization of the occlusive disease. This
finding is in keeping with some of the previous, limited, studies
evaluating Lp(a) in the same type of patients [10–15]. In 1992,
for the first time, Muller et al. reported increased Lp(a) levels in a
limited group of RVO patients when compared to healthy controls
[10]. Subsequently, other studies have confirmed such preliminary
findings in other, larger (although still limited) study populations
[11–15]. In our study, high Lp(a) levels have been found to be
associated with an increased risk of RVO, after multiple statistical
adjustments. This allows us to state that Lp(a) plays a relevant role
in the pathogenesis of RVO. On the other hand, however, two pre-
vious studies, one by our group and the other from the cohorts of
the ARIC and CHS studies did not observe an independent asso-
ciation between high Lp(a) levels and the occurrence of retinal
occlusive disease after correction for confounding factors, which
include other thrombophilic factors [5,16].
Some explanations can be identified for the discrepancy in the
results. First of all, the number of patients with RVO included in
the previous studies is extremely variable, being in some cases too
low to obtain reliable data. Secondly, the levels of Lp(a) found to
be associated with an increased risk of the disease differ from one
study to another. In the study by Wong et al. [16] an analysis of
quartiles of Lp(a) was conducted, whereas in the vast majority of
studies the cut-off of 300mg/Lwas used. Thirdly, themethods used
for the measurement of Lp(a) are different, especially in relation to
the sensitivity and specificity for the identification of thewide vari-
ation of the apo(a) molecular weight. This could explain, at least in
part, some of the differences observed in the studies that investi-
gatedLp(a) in associationwith thromboticdiseases [26]. Finally, the
parameters forwhich the statistical analysis has been adjusted vary
substantially. In one of our previous studies [5] Lp(a) was adjusted
for all the other thrombophilic risk factors, including some which
are strictly linked to Lp(a), such as PAI-1, whereas in most of the
other studiesno, or very limited, adjustmentshavebeenperformed.
RVO is one of the most common retinal vascular diseases,
with a low prevalence in the general population [1,2]. During the
few years, findings which demonstrate a significant association
between RVO and cardiovascular mortality have been reported, so
conferring on RVO an epidemiological relevance among vascular
disorders [3].
To date, the pathogenesis of RVO has not been completely clar-
ified [4]. A link between atherosclerotic risk factors and RVO has
been widely suggested by many studies. In particular, a relevant
role for hypertension has been reported. Indeed, almost all relevant
studies have recorded a strong and consistent link between hyper-
tension and the risk of RVO [1–4]. Our study population shows a
consistent number of patients with RVO who recorded high blood
pressure, thus hypothesising a possible influence of such a risk fac-
tor on the association between Lp(a) and the disease. However,
after adjustments for traditional risk factors comprising hyperten-
sion, Lp(a) still remains associated with an increased risk of RVO.
Recently, a meta-analysis by Janssen et al. [27] demonstrated that
factors known to contribute to the risk of atherosclerosismight also
be important in the pathogenesis of RVO, including some throm-
bophilic risk factors. In addition, we have also demonstrated in
a large group of patients with RVO that homocysteine, as well
as haemorheological variables and circulating vitamins, may pre-
dispose the occurrence of the disease [5–8]. Despite this, the full
pattern of possible risk factors in its pathology has not been inves-
tigated and some issues remain open in terms of the pathological
mechanisms that lead to the clinical thrombosis.
The present study, evaluating Lp(a) levels together with other
traditional and emerging thrombophilic risk factors, in a relevant
number of RVO patients and healthy subjects, support the previ-
ous evidence of a significant role of elevated levels of Lp(a) in the
occurrence of RVO.
The association between Lp(a) and RVO can be explained
by several mechanisms. Lp(a) can, in fact, act through dif-
ferent pathophysiological pathways to promote atherosclerosis
and thrombosis. Lp(a) has been reported to enter into human
atherosclerotic plaques and promote cholesterol accumulation in
macrophages which form foam cells [28]. Moreover, it has been
demonstrated that an interaction between Lp(a) and other lipid
variables including low-density lipoprotein can exist, acting pos-
sibly through the activation of the protease region of apo(a) and a
subsequent increase of the risk of atherothrombosis [29]. In addi-
tion, Lp(a) is able to promote smooth muscle cell proliferation
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and migration in atherosclerotic lesions by inactivating transform-
ing growth factor-beta [30], and, more importantly, to have an
inhibitory effect on fibrinolytic mechanisms due to its structural
similarity to plasminogen, which causes competition with plas-
minogen activators [31]. Other mechanisms that may contribute
towards thrombus formation include inactivation of the tissue
factorpathway inhibitor, thuspromotingcoagulation [31], andaug-
mentation of oxidative stress via generation of reactive oxygen
species [32].
Notably, the results obtained in the present study can be help-
ful in the clinical management of RVO patients. Up until now, no
established treatment for RVO is available. The increasing role of
hypercoagulability in these patients supports the use of antithrom-
botic drugs, butmedicalmanagement of patientswithRVOconsists
primarily of the treatment of the underlying systemic diseases. The
presence of an altered lipid profile, on the other hand, can give
physicians a further therapeutic option for the treatment of RVO
patients, even in the current absence of an established efficient
therapy for elevated Lp(a) levels. Some reports indicating the pos-
sible beneficial role of aspirin therapy in the management of RVO
and high Lp(a) levels have been reported, but data are very limited
[33]. Moreover, a possible beneficial effect of treatment with extra-
corporeal lipid-selective apheresis and niacin has been proposed
in patients with a vascular occlusive clinical event and markedly
elevated Lp(a) levels, thus possibly hypothesising a role for this
technique also for RVO, even if data supporting this approach are
limited [34].
In conclusion, the findings of the present study provide evi-
dence for the possible pathogenetic role of high levels of Lp(a)
on the occurrence of RVO, thus hypothesising the inclusion of
such a parameter in the evaluation of this type of thrombotic dis-
ease. Larger controlled trials are recommended to clarify whether
lipid-lowering techniques are beneficial in the treatment of these
patients.
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